Lupin has unveiled plans for a significant step up in the inhalation therapy segment, with back-to-back announcements on its efforts for a generic version of GlaxoSmithKline's blockbuster asthma/COPD product, Advair/Seretide (salmeterol/fluticasone), and the launch in the US of a device to enhance delivery of aerosol therapies.
Several firms including Sandoz, Mylan and Cipla are already entrenched in the generic Advair space though Lupin expects its deal...






